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High Performing Athletes
Does Cannabis Use Enhance Performance?
By Racine Ross
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Sha’Carri Richardson (far left) runs in the Women’s 100 Meter semifinal on day 2 of the 2020 U.S. Olympic Track and Field Team Trials at
Hayward Field on June 19, 2021 in Eugene, Ore. Image by jenaragon94 on Flickr. June 18, 2021.

June 19th, 2021

T

his was the day that
Sha’Carri Richardson’s
dream of going to
the 2021 Olympics was crushed.
Sha’Carri Richardson was predicted to be the big gun in the women’s 100-meter race after winning
with a time of 10.86 seconds in
the U.S. Olympic Track and Field
Trials. A turn of events occurred
when Richardson tested positive
for cannabis as a result of the
psychoactive component, THC.
Cannabis use, one of the numerous banned substances under the
United States Anti-Doping Agency
(USADA), results in a three-month
suspension if the athlete can
confirm that the substance use did
not occur within the competition
period and had no relation to their
sports performance. Additionally,
athletes can reduce their suspension to one month if they complete a substance abuse treatment
program with approval from the
USADA [1]. Insomuch as the Track
and Field Trials took place a mere
month before the start of the 2021

Olympics, Richardson had the
opportunity taken away from her
to represent the USA. Richardson
completed the counseling program as a result of her cannabis
use in response to cope with the
tragic news of her biological mother dying just weeks before the
start of the competition [2]. Athletes across the board have been
in situations like this, but as laws
are changing and research is being
conducted, the rules remain the
same for cannabis use in athletics.
Why is this the case?

Brief History Lesson
Cannabis has been present in this world since 4,000 B.C.E
originating in China. Its original
use was to treat ailments such as
gastrointestinal illnesses, seizures,
malaria, and pain associated with
childbirth. From that time, it made
its way through Asia, the Middle
East, and Africa. It did not appear
in America until 1545, though,
when the Spaniards brought the
hemp plant in hopes to make
good rope for the ships they were

building. Fast forward to the 19th
century, cannabis became more
popular and used for recreational purposes. Cannabis began
being used for numerous illnesses, plus drug companies began
constructing cannabis tinctures.
Subsequently, the Pure Food and
Drug Act of 1906 and the Harrison Narcotic Act of 1914 imposed
restrictions on alcohol which
indirectly increased recreational
use of cannabis. Harry Anslinger,
who was the first commissioner
of the Federal Narcotic Bureau
in 1930, attempted to eliminate
cannabis which led to the Marijuana Tax Act of 1937 [3]. This
tax act ensured that possession
of cannabis would result in legal
penalties which increased with the
implementation of the Boggs Act
of 1951 and the Narcotics Control
Act of 1956 [4] . Imposing a tax on
cannabis was declared illegal by
the Supreme Court in 1969 because imposing a tax on someone
who wants to possess an illegal
substance is considered a form of
self-incrimination. It was not until
1970 though when the Federal
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Drug Enforcement Agency (FDEA)
specified cannabis as a Schedule 1
drug, making medical and recreational use illegal [5]. As a schedule 1 controlled substance, cannabis has no accepted medicinal use,
high abuse potential, concerns for
dependence, and a lack of accepted safety for use under medical
supervision [4]. Despite this, in
1996 California enacted the Compassionate Use Act, which permits
legal access to and use of botanical cannabis for medicinal purposes under physician supervision.
This created a ripple effect in that
18 states have legalized cannabis
for recreational use, 38 states have
legalized cannabis for medical use,
and 32 states have decriminalized
cannabis and eliminated prohibition for the possession of small
amounts [6].

Protect and Serve
The justice system in the
United States was created to “protect and serve” its citizens, but it
does not do so equally. The “war
on drugs”, started by Richard Nixon in 1968, was created to reduce
the illegal drug trade in the United
States. Following this, our jails,
prisons, and courts experienced a
monstrous wave of rules and regulations while doing very little to
decrease the actual use of drugs
in communities. The United States
has seen a five-time increase in
incarcerations as compared to
1972, but there is no equivalent
decrease in drug use. Moreover,
discrepancies are found concerning the population that serves in
prison versus the rate and prevalence of drug use in the general
population. Rates of illicit drug use
are quite similar between Blacks
and Whites, with some lower numbers seen for Hispanics. Reporting
of drug use is commonly found in
communities of suburban, middle-class areas across the country.
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Marijuana plant and chemical structure of non-psychoactive compound: CBD.

Whites were 5 times more likely
to use cannabis than their Black
counterparts, but Black men are 13
times more likely to be admitted
to prison with similar drug charges
to White men and thus make up
60% of the prison population. In
some cases, there is a 26 to 27fold increase with this discrepancy.
This is not saying that Black men
are more likely to do drugs, just
that they are more likely to be
arrested and convicted. As a result
of these incarcerations, Blacks
have more difficulty finding work
as bosses are less likely to hire
people with previous track records.
Additionally, their social networks,
relationships, and families have all
suffered significantly. As demonstrated, the history of cannabis is
not only rooted in a plethora of
laws and regulations, but also a
severe discrepancy that disadvantages Blacks and Hispanics in an
already unequal society [7].

What is Cannabis?
Cannabis is a cannabinoid
that contains the psychoactive
compound delta-9-tetrahydrocan-

nabinol (THC) and non-psychoactive cannabidiol (CBD). The THC
in cannabis primarily acts on the
brain through the first cannabinoid
receptor (CB1) and the second
cannabinoid receptor (CB2). Each
of these receptors is a G-protein
coupled receptors (GPCRs) which
are a large number of receptors
that respond to various external
stimuli. Activating GPCRs causes the release of an intracellular
protein, known as a G protein,
which controls the activation of
an enzyme within the postsynaptic neuron. This activation then
communicates with the second
messenger, allowing the receptor
channel to open and potentially
affect additional processes in other
parts of the cell. CB1 receptors
have a high concentration in the
central nervous system (CNS) and
are the most common GPCRs
in the CNS 3. CB2 receptors are
primarily found in the tissues of
the immune system as well as the
heart. In 1964, the structure of the
main psychoactive compound,
now known as THC, was discovered by Mechoulam and Gaoni
[8]. Thus, this discovery allowed
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researchers to delve more deeply
into the world of cannabis.

The Ins and Outs
of THC
There are numerous neurotransmitters involved in the
mechanism of action for cannabis.
As illustrated in Figure 1, upon
inhaling a puff of cannabis containing THC, the CB1 receptors are
primarily activated. This activation
is dependent on two of the endogenous cannabinoids found in the
body which are anandamide (AEA)
and 2-arachidonoylglycerol (2-AG).
The cannabinoids inhibit the Ca2+
channels which in turn activate the
K+ channels, making the cell less
likely to release neurotransmitters.
As a result, there is an inhibitory
effect on the neurotransmitter
release of norepinephrine (NE),
dopamine (DA), gamma-aminobutyric acid (GABA), acetylcholine
(Ach), and glutamate (Glu). CB1
activation has been found to increase DA in the prefrontal cortex
(PFC), though, which is responsible for high cognitive functioning,
planning, and problem-solving. As
can be seen in Figure 2, there is a
disinhibition of pyramidal Glu neurons. The normal GABA release
onto these pyramidal Glu neurons
is now suppressed, allowing Glu
to be released onto the ventral
tegmental area (VTA) which plays a
role in drug addiction, behavioral
disorders, cognition, motivation,
and locomotor activity. The VTA
then projects onto the Nucleus Accumbens which then projects onto
the PFC and increases dopamine
in that region.

THC vs. CBD
CBD was first isolated from
cannabis in 1940 and its structure
was later reported in 1963. Unlike
THC, the most notable difference

Figure 1: The human endocannabinoids (AEA and 2-AG) can bind to the CB1 receptor as
well as THC molecules. Image created by Racine Ross with BioRender.com

for CBD is the fact that it is not a
psychoactive compound. In other
words, CBD has similar pharmacological effects to THC but does not
produce the high that you experience when consuming THC. CBD
does not have any impact on the
CB1 and CB2 receptors which typically produces the psychoactive
aspect, or high. CBD has increased
in popularity and is more heavily
studied with its possible health
benefits for the central nervous
system such as assisting with generalized anxiety, obsessive-compulsive disorder, panic disorder,
and psychosis [9]. Additionally,
CBD has been found to have
possible use as an antipsychotic,
anti-inflammatory, antiepileptic, as
well as for some neuroprotective
effects. Furthermore, some applications of CBD for medicinal use

have emerged such as in treating
pain (chronic and neuropathic), diabetes, cancer, and neurodegenerative diseases such as Huntington’s
disease [4].

Pharmacological
effects and Time
Course
Cannabis is known to have
psychotropic effects as well as
somatic effects such as analgesia,
antinociception (pain-blocking),
and orexigenia (appetite stimulant). When taken in low to moderate doses, pleasant side effects
can be seen such as euphoria,
elation, exhilaration, disinhibition,
hyperactivity, and an increase in
hunger. Additionally, users have
reported subjective effects includ-
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Figure 2. CB1 activation increases dopamine in the prefrontal cortex by allowing glutamate to be released onto the VTA as a result of
the inhibition of GABA on the glutamate neurons. The VTA acts on the NAcc which then acts on the PFC and increases dopamine in
that region. Image created with Biorender.com by Racine Ross.

ing feeling calm, relaxed, and in a
dream-like state. To boot, cannabis
is known to have anxiolytic effects,
so individuals may use it to aid in
relieving their stress and anxiety
[10]. On the contrary, when taken
in high doses, cannabis can induce
adverse effects such as anxiety,
tachycardia, and hypertension.
Cannabis has multiple
routes of administration but its
most effective and well-known is
smoking. When smoked cannabis
typically has peak plasma concentrations attained within 3-10
minutes [11]. Inhalation of cannabinoids bypasses the first-pass metabolism that usually takes place
when orally ingesting compounds.
First-pass metabolism occurs when
enzymes in the GI tract or liver can
significantly reduce the concentration of a drug that reaches the
bloodstream [3]. Cannabis rapidly
distributes into organs containing
high amounts of blood vessels
and then evening out into less
vascularized tissue. Much of the
THC absorbed is stored in body
fat where it is slowly released
from. Metabolism of THC takes
place by hepatic cytochrome P450
enzymes. In metabolizing THC,
its metabolites 11-hydroxy- THC
(11-OH-THC) and 11-carboxy-THC
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(11-COOH-THC) go through the
process of glucuronidation which
is excreted in feces and urine [11].
When identifying THC in urine
samples, the focus lies on identifying its inactive metabolite, 11-carboxy-THC. In compliance with the
World Anti-Doping Agency, testing
positive for cannabis is found when
the test detects 11-carboxy-THC
concentrations greater than 15
µg/L [13].
The amount of time it takes
for the plasma levels of THC to
fall to 50%, also known as a drug’s
half-life, varies depending on an
individual’s frequency of usage but
is typically around 20-30 hours.
Heavy users typically have a longer
half-life as a result of the slow
redistribution from fatty tissues.
In light users, who are individuals
that consume cannabis less than
twice per week, a positive urine
sample will occur for 1 to 3 days
after ceasing smoking. In regular smokers, who are individuals
that consume cannabis several
times per week, a positive urine
sample will occur for 7 to 21 days
after ceasing smoking. In chronic
smokers, who are individuals that
smoke daily for extended periods, a positive urine sample can
occur for 30 days or longer upon

ceasing smoking. Consequently,
testing positive does not technically mean that an individual has
recently smoked cannabis. There
is little to no correlation between
the presence of 11-carboxy-THC in
urine samples and the presence of
significant concentrations of THC
in the blood [3].

Do you use it too?
Cannabis is considered to be the
most commonly used federally illicit drug in the United States, with
about 18% of Americans using it
in 2019. Adolescent cannabis use
has varied since 1979 from 50%
to an all-time low of 22% and now
hovering around 36%. There also
appears to be a gender difference
among adolescents in which males
have a higher prevalence of daily
use of cannabis as compared to
females. Furthermore, daily use
is higher among Black and Hispanic adolescents as compared
to their White counterparts which
elucidates the racial stereotypes
associated with cannabis use in the
United States. These statistics are
found to be true for both adolescents and adults.
When looking at the young adult
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age group, there were significantly
higher rates of increased pastyear cannabis use as compared
to those in the older age groups.
Contrary to the adolescent age
group, cannabis use declined
among men in the adult age group
while the use in women remained
fairly constant. This decline is
consistent with the narrowing of
the gender gap in the frequency of heavy drinking and alcohol
problems. In addition to the racial
and ethnic disparities, an individual’s income also plays a role in
cannabis use across the United
States. Individuals with the lowest
incomes had the highest risk and
substantial rates of increase in
past-year cannabis use as well as
cannabis use disorder. Moreover,
men in adult households making
less than $50,00 have increased
prevalence than women in the
same situation.
As it happens, cannabis use
among pregnant women is more
common than we would like to
admit. Past-month cannabis use
increased to 62% among pregnant
women and 47% among non-pregnant reproductive-age women [5].
Thus, we can see that cannabis use
is prevalent across all age groups,
genders, ethnicities, socioeconomic backgrounds, and reproductive
statuses.

Do athletes use it
too?
A recent study conducted
in 2019 found that cannabis use
runs in second place following alcohol use among athletes. A study
conducted in 2011 found that
one-third of male and one-quarter
of female student-athletes in their
NCAA Division 1 school reported
using cannabis in the past year
[12]. Additionally, a study conducted in 2020 found that 1 in 4 athletes (23.4%) used cannabis in the

past year but the scientists who
conducted this study believe this
number may be underrepresented
of the actual number since they relied on athletes self-reporting their
use. These numbers are slightly
lower than we see in students who
don’t participate in athletics, but
it is also thought to believe that
student-athletes underreport their
cannabis use [10].

Does Cannabis use
show evidence for
enhancing
performance?
Now that we’ve got the
nitty-gritty information out of the
way, we can talk about what we
came to talk about: does cannabis
use show evidence for enhancing
performance? Studies upon studies are conducted, indicating how
exercise is essential for remaining
healthy in life. As cannabis becomes increasingly popular and
laws are changing around its use,
scientists have begun studying
cannabis use and its effects on

physical exercise performance.
There is a lack of strong evidence
showing that there is a relationship
between cannabis use and athletic
performance. Conversely, there are
proven to be adverse effects from
short-term and long-term cannabis use. On the short-term side,
cannabis use has been found to
result in impaired short-term memory, impaired motor coordination,
altered judgment, and paranoia
or psychosis in high doses. On the
long-term side, significantly heavy
cannabis use has been found to
result in chronic bronchitis and
increased risk of chronic psychosis-related health illnesses such as
schizophrenia, myocardial infarction stroke, and transient ischemic
attack [4]. Moreover, research
has found that long-term effects
may result in immunosuppression,
bronchial irritation and inflammation, and even reducing sperm
count and viability in men.
Additionally, a review
study conducted in 2018 found
that there are results that indicate
cannabis use negatively affects
an athlete’s performance. Thus,
cannabis is considered an ergo-
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Figure 3. Reward pathway in the brain. Image created with Biorender.com by Racine Ross.

lytic substance as opposed to an
ergogenic one. That is, cannabis is
a substance that impairs exercise
capacity and athletic performance
instead of enhancing it [10].
Although there is no evidence on
physical performance enhancement, there is some evidence
that may suggest that athletes
use cannabis due to the euphoric
subjective experience. As mentioned earlier, THC has anxiolytic
effects at low doses which is why
some athletes may depend on the
substance to relieve any anxiety
before competitions. Additionally, athletes have reported other psychological improvements
such as an increase in relaxation,
pleasure, and an improvement in
sleep. These factors do not directly affect performance, but there
is the chance that they can positively impact an athlete’s mindset,
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therefore indirectly affecting their
performance. One thing to note
though is that these psychological
factors have all been subjective
self-reports. There is no concrete
evidence that shows a direct relationship between cannabis use
and its influences on the mental
state of an athlete concerning the
management of their anxiety [10,
12].
Throughout the sporting
world, there are no consistent
penalties found when testing
positive for THC. The NFL and
National Basketball Association
have clearly defined penalties,
but the National Hockey League
has minimal penalties for athletes
testing positive. Moreover, there
is no consistency in an acceptable
level of THC. The NCAA will not
permit THC levels at a threshold
greater than 1.5 µg/l while the

World Anti-Doping Agency (WADA)
will permit THC levels at a threshold of 15 µg/l. On top of this, the
NCAA does not allow cannabis use
at any point of the season, while the
WADA only bans the substance at
the time of competition.
With all the aforementioned evidence, my question then is, why
does our society continue to view
cannabis as an illicit substance with
no accepted medical use? Why
are there numerous discrepancies
between levels of accepted concentrations or times at which cannabis
use may be appropriate? As Bob
Marley once said concerning cannabis use, “Herb. Herb is a plant.
Herb so good for everything. Why,
these people who want to do so
much good for everyone – who call
themselves governments and this
and that – why them say you must
not use the herb?” [14]
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